Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $2
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1.25 to $2.
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1.25 to $2.